Silence Therapeutics plc
Price Action
Technical Summary
STAGE 2 UPTRENDSilence Therapeutics plc is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 82% provides fundamental context to the price action. However, price is extended 37% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.33 | +21.86% | ABOVE |
| 50 SMA | $7.43 | +36.53% | ABOVE |
| 100 SMA | $6.70 | +51.38% | ABOVE |
| 150 SMA | $6.41 | +58.40% | ABOVE |
| 200 SMA | $6.35 | +59.83% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLN in an uptrend right now?
SLN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SLN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SLN overbought or oversold?
SLN's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is SLN outperforming the market?
SLN has a Relative Strength (RS) Rating of 93 out of 99. Yes, SLN is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is SLN in its 52-week range?
SLN is trading at $10.15, which is 92% of its 52-week high ($11.06) and 87% above its 52-week low ($4.19).
How volatile is SLN?
SLN has a Beta of 1.51 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.